Ocata Therapeutics, Inc. (OCAT)

Advanced Cell Technology, Inc. is a biotechnology company, incorporated in the state of Delaware, focused on developing and commercializing human embryonic and adult stem cell technology in the emerging fields of regenerative medicine. Principal activities to date have included obtaining financing, securing operating facilities, and conducting research and development.
The Company has no therapeutic products currently available for sale and does not expect to have any therapeutic products commercially available for sale for a period of years. The Company's revenues are generated from license and research agreements with collaborators.



Contact Information:
Business Address: | 33 Locke Drive, Marlborough, MA 01752, United States |
Mailing Address: | - |
Phone: | 508-756-1212 |
Fax: | 508-229-2333 |
Website: | http//www.advancedcell.com |
Company Details:
Symbol: | OCAT |
SIC: | - |
State location: | MA |
Sector: | - |
State of Inc: | DE |
Employees: | 48 |
Type: | - |
Key executives:
Name | Age | Position |
---|---|---|
Ivan Wolkind | 54 | Principal Financial Officer, Chief Accounting Officer, VP of Fin. and Controller |
Jonathan F. Atzen | 55 | Sr. VP, Sec. and Gen. Counsel |
Michael D. West Ph.D. | 67 | Pres, Chief Scientific Officer |
Robert P. Lanza M.D. | 64 | VP of Medical and Scientific Devel. |
William M. Caldwell IV | 72 | Chairman and CEO |